---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-359418"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2026-08-20T21:28:20+00:00"
generated_at: "2026-08-20T21:30:32.202553+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Amylyx prices $471.7M equity offering to fund avexitide launch

## Summary
- 14,090,000 shares at $35.50/share; 30-day option for 2,113,500 more.
- Net proceeds ~$471.7M (~$542.5M if option fully exercised).
- Proceeds to fund potential U.S. launch of avexitide, R&D, working capital.
- Offering expected to close Aug 21, 2026; underwriters: Leerink, Morgan Stanley, Guggenheim, LifeSci.

## SEC filing metadata
- accession: 0001193125-26-359418
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2026-08-20T21:28:20+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000119312526359418/0001193125-26-359418-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000119312526359418/d179247d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-359418
- JSON: https://secwatch.observer/filing/0001193125-26-359418.json
- Plain text: https://secwatch.observer/filing/0001193125-26-359418.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.